Howard R. Soule
A5058885329- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Statistical Methods in Clinical Trials
- Cell Adhesion Molecules Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Immune Response and Inflammation
- Cancer Immunotherapy and Biomarkers
- Heat shock proteins research
- Hippo pathway signaling and YAP/TAZ
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- Global Cancer Incidence and Screening
- Ethics in Clinical Research
- Blood Coagulation and Thrombosis Mechanisms
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
Prostate Cancer Foundation
2016-2025
Fred Hutch Cancer Center
2022
University of Washington
2022
University of British Columbia
2022
Institute of Oncology Research
2022
Instituto de Investigación Biomédica de Málaga
2022
Guy's and St Thomas' NHS Foundation Trust
2022
Tel Aviv University
2022
Memorial Sloan Kettering Cancer Center
2004-2020
Institut Gustave Roussy
2020
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for ten most important areas of controversy in advanced prostate cancer (APC) management. successful registration several drugs castration-resistant recent studies chemo-hormonal therapy men with castration-naïve have led to considerable uncertainty as best treatment choices, sequence options appropriate patient selection. Management recommendations based on...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA).A states framework was used address hypothesis that definitive phase III trials could not be conducted this patient population.The Group focused on men with systemic (nonlocalized) recurrence and defined risk developing clinically detectable metastases. Models versus local recurrence, metastatic progression were discussed.Therapies have shown favorable effects more advanced...
We tested the neuroprotective potential of neutrophil inhibitory factor (rNIF), a novel 41-kd recombinant glycoprotein derived from hookworm, in model focal cerebral ischemia rat. Male Wistar rats were assigned to treatment with rNIF and vehicle. Middle artery occlusion (MCAO) for 2 hours was induced by insertion an intraluminal suture. Infusion drug initiated at onset reperfusion. Infarct volume determined 48 after Neutrophils measured within ischemic tissue myeloperoxidase (MPO) staining....
Abstract Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field prostate research hindered by lack relevant preclinical models study tumorigenesis further development effective prevention therapeutic strategies. Cancer Foundation held Models Working Group (PCMWG) Summit on August 6th 7th, 2007 address these issues. PCMWG reviewed state identified current limitations cell line, xenograft genetically engineered mouse that have hampered...
Neutrophil inhibitory factor (NIF) is a hookworm-derived glycoprotein ligand of the integrin CD11b/CD18 that inhibits human neutrophil function (Moyle, M., Foster, D. L., McGrath, E., Brown, S. Laroche, Y., De Meutter, J., Stanssens, P., Bogowitz, C. A., Fried, V. Ely, J. Soule, H. R., and Vlasuk, G. P. (1994) Biol. Chem. 269, 1008-10015). Here, we present evidence recombinant NIF (rNIF) associates with approximately 200-amino acid residue I domain this interaction essential for inhibition...
Gram-negative sepsis is oftentimes complicated by activation of coagulation with disseminated intravascular and microthrombosis. This may contribute to the associated morbidity, multiple organ failure death. Recent studies have established that tissue factor-dependent pathway blood has a significant participatory role in initial endotoxin-induced coagulation. Tissue factor (TF), expressed on surface activated monocytes endothelial cells forms cell complexes free circulating factors VII VIIa....
The distribution of simian virus 40 large tumor antigen in subcellular fractions from 40-transformed hamster (H-50) and mouse (VLM) cells 40-infected monkey was determined. Solubilized [ 35 S]-methionine- or 32 P i -labeled surface membrane nuclear were prepared, immunoprecipitated with anti-T serum, analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Tumor an apparent molecular weight ∼96,000 detected both fractions. Minor components ∼68,000 ∼56,000 reactivity which...
Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in and overexpressed multiple malignancies. TROP-2 therapeutic target for antibody–drug conjugates (ADC). Experimental Design: gene (TACSTD2) expression markers of treatment from biopsies were analyzed...